Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Rezolsta

REZOLSTA 600 mg/90 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 46–47

HOS-220558 · Präparat HOS-216626

46  Dabigatran etexilate dabigatran etexilate (150 mg): Clinical monitoring and dose Edoxaban darunavir/cobicistat 800/150 mg reduction is required when a single dose: DOAC transported by P-gp but dabigatran AUC ↑ 164% not metabolised by CYP3A4, dabigatran Cmax ↑ 164% including dabigatran etexilate and edoxaban, is co-administered darunavir/cobicistat 800/150 mg with REZOLSTA. once daily: dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Concomitant administration of Ticagrelor Based on theoretical REZOLSTA with ticagrelor is considerations co-administration contraindicated (see section 4.3). of REZOLSTA with ticagrelor may increase concentrations of ticagrelor. (CYP3A and/or P-glycoprotein inhibition). Co-administration of Clopidogrel REZOLSTA with clopidogrel is Based on theoretical not recommended. Use of other considerations co-administration antiplatelets not affected by CYP of REZOLSTA with clopidogrel is inhibition or induction (e.g. expected to decrease clopidogrel prasugrel) is recommended (see active metabolite plasma section 4.3). concentration, which may reduce the antiplatelet activity of clopidogrel. Warfarin Based on theoretical It is recommended that the considerations REZOLSTA may international normalised ratio alter warfarin plasma (INR) be monitored when concentrations. warfarin is co-administered with REZOLSTA. ANTICONVULSANTS Carbamazepine Based on theoretical Co-administration of Phenobarbital considerations these REZOLSTA and these Phenytoin anticonvulsants are expected to anticonvulsants is contraindicated decrease darunavir and/or (see section 4.3). cobicistat plasma concentrations. (CYP3A induction) Clonazepam Based on theoretical Clinical monitoring is considerations REZOLSTA is recommended when expected to increase co-administering REZOLSTA concentrations of clonazepam. with clonazepam. (inhibition of CYP3A) ANTI-DEPRESSANTS Herbal supplements Based on theoretical Co-administration of St John’s Wort considerations St John’s Wort is St John’s Wort and REZOLSTA expected to decrease darunavir is contraindicated (see and/or cobicistat plasma section 4.3). concentrations. (CYP3A induction)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) phenobarbital (HOS-085617) carbamazepine (HOS-085618) dabigatran (HOS-112096) clonazepam (HOS-116372) clopidogrel (HOS-087927) edoxaban (HOS-086234) prasugrel (HOS-112066) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)